Boston Biotech nChroma Bio Halts Its Only Clinical Trial and Cuts About Half Its Staff
Boston’s nChroma Bio said Wednesday, Nov. 18, it stopped dosing in its only trial, a hepatitis B study, and is cutting about half its staff. What we know.
World News, Politics and War, Reported from Boston
Boston’s nChroma Bio said Wednesday, Nov. 18, it stopped dosing in its only trial, a hepatitis B study, and is cutting about half its staff. What we know.